


HRP-VC-PAB-MMAF (1:1) Conjugate

Product Number: **CM53217**

Lyophilized powder, 0.5 mg per vial, ≥99% conjugates by SEC HPLC



Product Description

Monomethyl auristatin F (MMAF) is a new antimetabolic auristatin derivative with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE (references 1 & 2). This HRP-MMAF conjugate is designed with similar linker chemistry as ADCs prepared by our customer using CellMosaic's Antibody MMAF Conjugation Kit (with VC-PAB linker) (Cat#: CM11425). The conjugate is synthesized at CellMosaic for the customer's use in horseradish peroxidase (HRP) based assay. A long flexible PEG linker is also incorporated in the conjugate to retain the HRP activity and MMAF binding. The final conjugate is HPLC-purified to obtain 1:1 MMAF-labeled HRP conjugate and is lyophilized from PBS containing sugar-based stabilizer for easy shipping and storage.

The product is sold as 1 vial of 0.5 mg (Cat# CM53217-0.5MG) or 4 vials of 0.5 mg (Cat# CM53217-2MG). For bulk orders, please contact us for a quote.

Application

- Assay development for the quantitation and detection of MMAF labeled biopolymers (ADC and PDC) and MMAF drug released from the conjugate.
- Indirect and competitive ELISA assay

Key Features

- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
- HPLC-purified single-labeled conjugate, 1:1 HRP-MMAF.
- Retained HRP activity, 200–300 units/mg protein (1 unit is the amount of enzyme that will form 1.0 mg purpurogallin from pyrogallol in 20s at pH 6.0 at 20°C).
- A long flexible PEG linker is incorporated to retain the HRP activity and MMAF binding.
- Amount accurately determined by UV/HPLC analysis.

Storage/Stability

- Recommended storage of the product is below -20°C
- Expiration before defrosting is 1 year after receiving.
- Once defrosted maintain at 2-8°C.
- For best quality use within 1 week of defrosting.

Selected References

- 1) Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. *Bioconjug Chem* **2006**;17: 114–24.
- 2) Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. *Cancer Res.* **2009**;69(6):2358–2364.